Portal de Periódicos da CAPES

Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer

2016; Springer Nature; Volume: 114; Issue: 2 Linguagem: Inglês

10.1038/bjc.2015.448

1532-1827

Duncan C. Gilbert, Eva Serup‐Hansen, Dorte Linnemann, Estrid Høgdall, Charles Bailey, Jeff Summers, Hanne Havsteen, Gareth J. Thomas,

Colorectal Cancer Surgical Treatments

The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV− patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group. Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs). Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006). Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.